Femarelle® and bone mineral density - Scientific substantiation of a health claim related to “Femarelle®” and “induces bone formation and increases bone mineral density reducing the risk for osteoporosis and other bone disorders” pursuant to Article 14 of the Regulation (EC) No 1924/2006[1] - Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies

Tabs

Article
Panel on Dietetic Products, Nutrition and Allergies
doi
10.2903/j.efsa.2008.785
Panel members at the time of adoption
Jean-Louis Bresson, Albert Flynn, Marina Heinonen, Karin Hulshof, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Andreu Palou, Hildegard Przyrembel, Seppo Salminen, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Henk van den Berg, Hendrik van Loveren and Hans Verhagen.
Acknowledgements

The European Food Safety Authority wishes to thank Olivier Bruyère and the members of the
Working Group for the preparation of this opinion: Jean-Louis Bresson, Albert Flynn, Marina
Heinonen, Hannu Korhonen, Ambroise Martin, Andreu Palou, Hildegard Przyrembel, Seppo
Salminen, Sean (J.J.) Strain, Inge Tetens, Henk van den Berg, Hendrik van Loveren and Hans
Verhagen.

Type
Opinion of the Scientific Committee/Scientific Panel
Question Number
EFSA-Q-2008-078
Adopted
4 August 2008
Published in the EFSA Journal
21 August 2008
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Abstract

No abstract available

Keywords
Bone formation, bone mineral density, osteoporosis, post-menopausal women